VRPX: Virpax Pharmaceuticals, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 2.35
Enterprise Value ($M) 0.48
Book Value ($M) -2.79
Book Value / Share -0.57
Price / Book -0.84
NCAV ($M) -2.79
NCAV / Share -0.57
Price / NCAV -0.84

Profitability (mra)
Return on Invested Capital (ROIC) n/a
Return on Assets (ROA) -1.32
Return on Equity (ROE) -2.65

Liquidity (mrq)
Quick Ratio 0.48
Current Ratio 0.48

Balance Sheet (mrq) ($M)
Current Assets 2.59
Assets 2.59
Liabilities 5.39
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income 0.00
Net Income 0.00

Cash Flow Statement (mra) ($M)
Cash From Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)
Change
(%)
05-23 13G Intracoastal Capital, Llc 4.99
01-02 13G/A Sabby Management, Llc 0.00 -100.00

Top 13F Investors Shares
(1000)
Change
(%)
Value
($1000)
Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-08-12 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO S
2024-05-13 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO
2024-03-26 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2023 ☐ TRANSITION REPORT PURSUA
2023-12-07 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPORT PURSUANT

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-10-09 2,863 36,934 7.75
2024-10-08 1,339 94,699 1.41
2024-10-07 26,505 408,431 6.49
2024-10-04 1,318 19,562 6.74

(click for more detail)

Similar Companies
VINC – Vincerx Pharma, Inc. VIRX – Viracta Therapeutics, Inc.
VKTX – Viking Therapeutics, Inc. VSTM – Verastem, Inc.
VTGN – Vistagen Therapeutics, Inc.


Financial data and stock pages provided by
Fintel.io